Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound medicinal composition for ophthalmology and preparation method thereof

A composition and ophthalmology technology, applied in the directions of drug combination, pharmaceutical formula, medical preparation containing active ingredients, etc., can solve problems such as defects, damage to the visual field at the optic nipple, and achieve the effect of reducing the level of intraocular pressure

Inactive Publication Date: 2014-03-19
TIANJIN ALCMIT TECH CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Open-angle glaucoma is an eye disease that causes irreversible damage to the optic nerve head and visual field defect due to elevated intraocular pressure, and finally leads to blindness. There is currently no cure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound medicinal composition for ophthalmology and preparation method thereof
  • Compound medicinal composition for ophthalmology and preparation method thereof
  • Compound medicinal composition for ophthalmology and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] prescription:

[0022] Element use Dosage Brimonidine tartrate active ingredient 0.2g (equivalent to brimonidine 0.13g) Levobetaxolol Hydrochloride active ingredient 0.56g (equivalent to 0.5g of levobetaxolol) Benzalkonium chloride preservative 0.005g Sodium citrate buffer 0.45g polyvinyl alcohol additive 1.0g Edetate disodium Antioxidants 0.01g Sodium chloride Isotonic agent 0.9g Sodium Hydroxide and Hydrochloric Acid pH regulator Adjust pH5.6~6.6 Water for Injection solvent Add to 100ml

[0023] Process:

[0024] (1) Weigh the prescribed amount of polyvinyl alcohol, add appropriate amount of water for injection to dissolve;

[0025] (2) Weigh the prescribed amount of sodium citrate, sodium chloride, edetate disodium, benzalkonium chloride, brimonidine tartrate and levobetaxol hydrochloride into a sterilized container, add appropriate amount Water for injection, stir to disso...

Embodiment 2

[0028] prescription:

[0029] Element use Dosage Brimonidine tartrate active ingredient 0.15g (equivalent to brimonidine 0.10g) Levobetaxolol Hydrochloride active ingredient 0.56g (equivalent to 0.5g of levobetaxolol) Benzalkonium chloride preservative 0.005g Sodium citrate buffer 0.45g polyvinyl alcohol additive 1.0g Edetate disodium Antioxidants 0.01g Sodium chloride Isotonic agent 0.9g Sodium Hydroxide and Hydrochloric Acid pH regulator Adjust pH6.6~7.4 Water for Injection solvent Add to 100ml

[0030] Process:

[0031] (1) Weigh the prescribed amount of polyvinyl alcohol, add appropriate amount of water for injection to dissolve;

[0032] (2) Weigh the prescribed amount of sodium citrate, sodium chloride, edetate disodium, benzalkonium chloride, brimonidine tartrate and levobetaxol hydrochloride into a sterilized container, add appropriate amount Water for injection, stir to diss...

Embodiment 3

[0035] prescription:

[0036] Element use Dosage Brimonidine tartrate active ingredient 0.10g (equivalent to brimonidine 0.07g) Levobetaxolol Hydrochloride active ingredient 0.56g (equivalent to 0.5g of levobetaxolol) Benzalkonium chloride preservative 0.005g Sodium citrate buffer 0.45g polyvinyl alcohol additive 1.0g Edetate disodium Antioxidants 0.01g Sodium chloride Isotonic agent 0.9g Sodium Hydroxide and Hydrochloric Acid pH regulator Adjust pH7.4~8.0 Water for Injection solvent Add to 100ml

[0037] Process:

[0038] (1) Weigh the prescribed amount of polyvinyl alcohol, add appropriate amount of water for injection to dissolve;

[0039] (2) Weigh the prescribed amount of sodium citrate, sodium chloride, edetate disodium, benzalkonium chloride, brimonidine tartrate and levobetaxol hydrochloride into a sterilized container, add appropriate amount Water for injection, stir to diss...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound medicinal composition for ophthalmology. The compound medicinal composition contains brimoxidine and levobetaxolol, wherein the concentration of the brimoxidine is 0.07-0.33 percent (W / V); and the concentration of the levobetaxolol is 0.25-0.5 percent (W / V). The brimoxidine and the levobetaxolo prepared by the invention can be used for remarkably reducing the intraocular pressure level and is beneficial to treating glaucoma diseases.

Description

technical field [0001] The invention relates to a compound ophthalmic pharmaceutical composition and a preparation method thereof, in particular to a compound ophthalmic pharmaceutical composition for treating glaucoma and a preparation method thereof. Background technique [0002] Open-angle glaucoma is an eye disease that causes irreversible damage to the optic nerve head and visual field defect due to elevated intraocular pressure, and finally leads to blindness. There is currently no cure. Elevated eye pressure is usually caused by excessive production of water in the eye, poor drainage of water, or both. Therefore, reducing the formation of intraocular water and increasing the discharge of water can help reduce intraocular pressure, and choosing drugs with neuroprotective effects while reducing intraocular pressure is more helpful for the treatment of such diseases. [0003] Alfagen (brimonidine) is an alpha-2 adrenergic receptor agonist with a dual mechanism of action...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/498A61K31/138A61P27/06
Inventor 齐平刘翠翠陈琴其他发明人请求不公开姓名
Owner TIANJIN ALCMIT TECH CO LTD